United StatesHealth

Cycurion closed 2025 with a strong financial position, reporting an $80 million contracted backlog and bolstered liquidity as the company accelerates into 2026.

For the third quarter of 2025, Cycurion, which trades on the Nasdaq under the ticker CYCU, reported revenue of $3.83 million, a 13.9% year-over-year decrease. However, total assets grew to $32.31 million, an increase of 26.4%, and cash reserves rose significantly to $3.65 million, compared to just $0.04 million at the end of 2024.

The company saw net financing inflows of $10.78 million and is forecasting a Q1 2026 run-rate revenue of approximately $4.17 million, which would annualize to around $16.66 million.

Recent business wins include a multi-year telecom deployment with potential revenue exceeding $1 million, a state and local government data modernization project, and a $1.1 million county contract. Cycurion also declared a pro-rata share dividend of $0.0080 per share, payable around December 30, 2025.

Cycurion’s strategic focus on government and commercial sectors continues to drive growth as the company strengthens its foundation for expansion into 2026.

Denali Therapeutics (NASDAQ:DNLI) announced promising Phase 1/2 results for tividenofusp alfa (DNL310) in the treatment of Hunter syndrome, with the data published in The New England Journal of Medicine supporting an FDA Priority Review. The FDA has set a Prescription Drug User Fee Act (PDUFA) date for April 5, 2026.

Silo Pharma (NASDAQ:SILO) announced a non-binding Letter of Intent (LOI) with Allucent (US) LLC to support the Phase 1 clinical development of SPC-15, a nasal spray formulation under investigation.

XOMA Royalty (NASDAQ:XOMA) announced the amendment of its 2006 collaboration agreement with Takeda (NYSE:TAK), marking a strategic shift in the economics of their partnership.

The deal, announced on Dec. 30, 2025, will see Takeda regain the majority of XOMA Royalty's economics related to mezagitamab, a monoclonal antibody for inflammatory diseases.

IM Cannabis Corp. (NASDAQ:IMCC) announced on Tuesday that it has launched a comprehensive review of strategic options to enter the United States cannabis market.

The pivot follows a landmark executive order signed by President Donald Trump on Dec. 18, 2025, which directs the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).

InflaRx N.V. (NASDAQ:IFRX) provided an update on its Phase 3 study of vilobelimab in pyoderma gangrenosum (PG), outlining multiple data analyses after the trial was terminated earlier this year due to futility, following a recommendation from an Independent Data Monitoring Committee (IDMC).

Evogene (NASDAQ:EVGN), a leader in computational chemistry and generative AI for life sciences, announced the appointment of Dr. Olga Nissan as Vice President of Business Development, effective Jan. 1, 2026.

EUDA Health Holdings (NASDAQ:EUDA) has unveiled a nationwide stem cell extraction, cryostorage, and clinical delivery platform in China, marking a massive expansion of its footprint in the regional longevity and regenerative medicine sector.

MetLife Investment Management (MIM), the institutional asset management arm of MetLife (NYSE:MET), has finalized its acquisition of PineBridge Investments, significantly expanding its global footprint and total assets under management to $734.7 billion.

HUTCHMED (NASDAQ:HCM) announced on Tuesday that Chinese regulators have accepted its New Drug Application (NDA) for savolitinib and granted it priority review, clearing a path for the drug to become the first selective MET inhibitor approved for gastric cancer in the region.

Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) have begun an aggressive price-cutting campaign for their blockbuster obesity treatments in China, as the two pharmaceutical giants race to capture the world's largest patient population before local generic competition arrives.

ARS Pharmaceuticals (NASDAQ:SPRY) said China’s drug regulator has approved neffy 2 mg, an epinephrine nasal spray, for the emergency treatment of Type 1 allergic reactions in adults and children weighing at least 30 kilograms, marking the first epinephrine product authorized for community use in the country.